Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  BioArctic AB    BIOA B   SE0010323311

BIOARCTIC AB

(BIOA B)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

BioArctic AB : annual earnings release

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/11/2019 | 09:15am EDT

The company will report its earnings for FY 2018 on 02/14/2019. Generally, the company reports earnings worse than estimates. In recent months, the 2 analysts from Thomson Reuters consensus have revised their EPS estimates upward.

Annual earnings per share is expected at 0.06 SEK for 2018 (- 72.7% from 2017). A summary of annual publications and estimates is available below.

Annual results20172018 (e)2019 (e)
Sales
Million SEK
Released
Forecast
Spread
141
120
18%

262

675
Operating income (EBITDA)
Million SEK
Released
Forecast
Spread
19,3
-12,0
261%

14,5

337
Operating profit (EBIT)
Million SEK
Released
Forecast
Spread
19,3
-13,5
243%

14,5

335
Pre-Tax Profit (EBT)
Million SEK
Released
Forecast
Spread
19,7
-35,0
156%

-58,0

329
Net income
Million SEK
Released
Forecast
Spread
15,2
-35,0
143%

-58,0

257
EPS
 SEK
Released
Forecast
Spread
0,22
-0,17
233%

0,06

2,96
Announcement Date02/20/2018

© MarketScreener.com 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BIOARCTIC AB
04/16BIOARCTIC : publishes the Annual Report for 2018
AQ
04/10BIOARCTIC : Notice of annual general meeting in bioarctic ab (publ)
AQ
04/03BIOARCTIC : receives grant from Vinnova for a collaborative research project to ..
AQ
03/25EISAI : Initiation of phase iii clinical trial of ban2401 in early alzheimer's d..
AQ
03/25EISAI : To present latest research on alzheimer's disease, dementia pipeline at ..
AQ
03/25BIOARCTIC : partner Eisai to give poster presentations on BAN2401 in early Alzhe..
AQ
03/23BIOARCTIC : s Partner Eisai Initiates the Confirmatory Phase 3 Study of BAN2401 ..
AQ
03/21BIOARCTIC : partner Eisai initiates the confirmatory Phase 3 study of BAN2401 in..
AQ
03/21BIOARCTIC : Statement regarding today's trading halt
AQ
03/13BIOARCTIC : announces start of Phase 1 study of ABBV-0805 for Parkinson's diseas..
AQ
More news
Financials (SEK)
Sales 2019 320 M
EBIT 2019 83,6 M
Net income 2019 81,0 M
Finance 2019 1 138 M
Yield 2019 -
P/E ratio 2019 109,52
P/E ratio 2020
EV / Sales 2019 15,0x
EV / Sales 2020 105x
Capitalization 5 930 M
Chart BIOARCTIC AB
Duration : Period :
BioArctic AB Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOARCTIC AB
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Average target price 154  SEK
Spread / Average Target 91%
EPS Revisions
Managers
NameTitle
Gunilla Christina Osswald President & Chief Executive Officer
Wenche Nelly A. Rolfsen Sandsborg Chairman
Jan P. Mattsson Chief Financial Officer & Vice President-Finance
Christer Möller CSO & VP-Pre-Clinical Development
Hans Basun Chief Medical Officer & VP-Clinical Development
Sector and Competitors
1st jan.Capitalization (M$)
BIOARCTIC AB-1.83%641
IQVIA HOLDINGS INC13.89%26 146
CELLTRION, INC.--.--%23 477
LONZA GROUP14.29%21 459
INCYTE CORPORATION21.06%15 924
EXACT SCIENCES CORPORATION45.50%11 546